Yoshuantari, Naomi and Jeng, Yung-Ming and Liau, Jau-Yu and Lee, Chia-Hsiang and Tsai, Jia-Huei (2023) Hepatic Sarcomatoid Carcinoma Is an Aggressive Hepatic Neoplasm Sharing Common Molecular Features With Its Conventional Carcinomatous Counterparts. Modern Pathology, 36 (1): 100042. pp. 1-9. ISSN 08933952
540.pdf - Published Version
Restricted to Registered users only
Available under License Creative Commons Attribution.
Download (3MB) | Request a copy
Abstract
Hepatic sarcomatoid carcinoma is a rare hepatic tumor with an aggressive clinical behavior and dismal outcome. However, the molecular pathogenesis is incompletely defined. In this study, we analyzed 59 hepatic sarcomatoid carcinomas using targeted next-generation sequencing and immunohistochemistry. A panel of 14 genes commonly mutated in primary liver carcinomas was examined. PD-L1 and loss of expression for switch/sucrose nonfermenting complexes, including BAP1, ARID1A, ARID2, and PBRM1, were detected by immunohistochemistry. The 59 hepatic sarcomatoid carcinomas encompass various carcinomatous subtypes and tumors with complete sarcomatoid transformation. Mutations in TP53 and promoter of TERT (pTERT) were frequently identified in sarcomatoid hepatocellular carcinoma, sarcomatoid combined hepatocellular cholangiocarcinoma, and hepatic sarcomatoid carcinomas with complete sarcomatoid transformation but rarely in sarcomatoid cholangiocarcinoma. Alterations involving switch/sucrose nonfermenting complexes were uncommon in hepatic sarcomatoid carcinoma (n = 2). PD-L1 expressed in tumor-associated immune cells in 67 of the tumors and in tumor cells in 33 of the tumors. A multivariate survival analysis indicated that PD-L1 expression in immune cells served as an independent favorable predictive factor of patient survival (P =.036). In conclusion, hepatic sarcomatoid carcinoma displays molecular similarity with its conventional carcinomatous counterparts. This finding suggests persistent genetic characteristics during sarcomatous evolution. PD-L1 expression in immune cells is a favorable prognostic factor for patient outcomes and may be a potential biomarker for immunotherapeutic treatment. © 2022 United States & Canadian Academy of Pathology
Item Type: | Article |
---|---|
Additional Information: | Cited by: 4 |
Uncontrolled Keywords: | B7-H1 Antigen; Carcinoma, Hepatocellular; Cholangiocarcinoma; Humans; Liver Neoplasms; Sarcoma; akt1 protein; alpha fetoprotein; arid2 protein; B Raf kinase; bap1 protein; carcinoembryonic antigen; ctnnb1 protein; cytokeratin AE1; cytokeratin AE3; epidermal growth factor receptor; epidermal growth factor receptor 2; epidermal growth factor receptor 3; gnas protein; isocitrate dehydrogenase 1; isocitrate dehydrogenase 2; K ras protein; MyoD1 protein; nras protein; pbrm1 protein; pik3ca protein; programmed death 1 ligand 1; protein p53; retinoblastoma binding protein 2; smooth muscle actin; sucrose; unclassified drug; programmed death 1 ligand 1; adult; aged; Article; bile duct carcinoma; cancer survival; clinical feature; DNA extraction; female; gene mutation; genetic analysis; genetic trait; hepatectomy; hepatic sarcomatoid carcinoma; hepatocellular cholangiocarcinoma; high throughput sequencing; human; human tissue; immunocompetent cell; immunohistochemistry; liver cell carcinoma; liver tumor; major clinical study; male; middle aged; molecular biology; multivariate analysis; pathogenesis; predictive value; promoter region; protein expression; sarcomatoid carcinoma; segmentectomy; survival analysis; treatment outcome; very elderly; bile duct carcinoma; genetics; liver cell carcinoma; liver tumor; pathology; sarcoma |
Subjects: | R Medicine > RB Pathology R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) |
Divisions: | Faculty of Medicine, Public Health and Nursing > Public Health and Nutrition |
Depositing User: | Ngesti Gandini |
Date Deposited: | 15 Aug 2024 07:49 |
Last Modified: | 15 Aug 2024 07:49 |
URI: | https://ir.lib.ugm.ac.id/id/eprint/3048 |